| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | CHUN-JEN LIU ; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | |||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; PO-HUANG LEE ; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | |||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; REY-HENG HU ; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | |||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO ; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | World Journal of Gastroenterology | |||
| 2014 | Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence | Liu C.-J.; Chang J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin Y.-J.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Yang M.-D.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN | World Journal of Gastroenterology | |||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | CHUN-JEN LIU ; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | |||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; PO-HUANG LEE ; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | |||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; REY-HENG HU ; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | |||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO ; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. | Journal of Hepatology | |||
| 2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN | Journal of Hepatology | |||
| 2021 | Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study | HSIEN-YI CHIU ; Chiu Y.-M.; Chang Liao N.-F.; Chi C.-C.; Tsai T.-F.; Hsieh C.-Y.; Hsieh T.-Y.; Lai K.-L.; Chiu T.-M.; Wu N.-L.; Hui R.C.-Y.; Lee C.-N.; Wang T.-S.; Chen P.-H.; Yang C.-C.; Huang Y.-H. | Journal of the American Academy of Dermatology | |||
| 2021 | Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study | Chiu H.-Y.; Chiu Y.-M.; Chang Liao N.-F.; Chi C.-C.; TSEN-FANG TSAI ; Hsieh C.-Y.; Hsieh T.-Y.; Lai K.-L.; Chiu T.-M.; Wu N.-L.; Hui R.C.-Y.; Lee C.-N.; Wang T.-S.; Chen P.-H.; Yang C.-C.; Huang Y.-H. | Journal of the American Academy of Dermatology | |||
| 2019 | The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial | Cheng A.; Hsieh S.-M.; SUNG-CHING PAN ; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; Chang S.-C. | Journal of Microbiology, Immunology and Infection | |||
| 2019 | The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial | ARISTINE CHENG ; Hsieh S.-M.; Pan S.-C.; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; Chang S.-C. | Journal of Microbiology, Immunology and Infection | |||
| 2019 | The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial | Cheng A.; Hsieh S.-M.; Pan S.-C.; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; SHAN-CHWEN CHANG | Journal of Microbiology, Immunology and Infection | |||
| 2019 | The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial | Cheng A.; SZU-MIN HSIEH ; Pan S.-C.; Li Y.-H.; Hsieh E.-F.; Lee H.-C.; Lin T.-W.; Lai K.-L.; Chen C.; Shi-Chung Chang S.; Chang S.-C. | Journal of Microbiology, Immunology and Infection |
